57356-31-7

Usage

Appearance

Yellow crystalline solid

Usage

Manufacturing of pharmaceuticals, dyes, and other organic compounds

Functional groups

Hydroxymethyl group, nitro group in the phenol ring

Versatility

Suitable for various applications

Application in organic synthesis

Used as a reagent

Role in chemical synthesis

Serves as a starting material for the synthesis of other chemicals

Value

Valuable compound in the field of chemistry and industry

Upstream product

• 50603-42-4 5-nitro-1,3-benzodioxane 
• 111742-62-2 (2-(bromomethyl)-3-nitrophenoxy)(tert-butyl)dimethylsilane 
• 5460-31-1 3-nitro-o-cresol 
• 18173-64-3 tert-butyldimethylsilanol 

Downstream Products

• 19689-87-3 (2-methoxy-6-nitrophenyl)methanol 
• 16855-08-6 2-hydroxy-6-nitrobenzaldehyde 
• 844642-87-1 2-amino-6-hydroxyl-benzyl alcohol 
• 358365-66-9 2-[2-(2-tert-butoxycarbonylamino-3-hydroxy-propyl)-3-methoxy-phenylamino]-3-methyl-butyric acid benzyl ester 
• 198781-81-6 2-[2-(2-tert-butoxycarbonylamino-3-hydroxy-propyl)-3-methoxy-phenylamino]-3-methyl-butyric acid 
• 331819-80-8 [1-hydroxymethyl-2-(2-methoxy-6-nitro-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 331819-82-0 [2-(2-amino-6-methoxy-phenyl)-1-hydroxymethyl-ethyl]-carbamic acid tert-butyl ester 
• 331819-79-5 2-amino-3-(2-methoxy-6-nitro-phenyl)-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

Total Synthesis and Absolute Stereochemical Assignment of the Insecticidal Metabolites Yaequinolones J1 and J2

A highly stereocontrolled total synthesis of (-)-yaequinolone J1 and (+)-yaequinolone J2 was accomplished using an Evans auxiliary to establish a syn-diol unit in an acyclic appendage to a preformed benzopyran core bearing a homoprenyl group. The first to

INSULIN ANALOGUES

A dicarba analogue of insulin comprising an A-chain and a B-chain or fragments, salts, solvates, derivatives, isomers or tautomers of the A-chain, the B-chain or both, provided that the dicarba analogue is not [A7,B7-(2,7-diaminosuberoyl]-des-(B26-B30)-insulin B25-amide.

Non-nucleoside reverse transcriptase inhibitors

Compounds represented by formula I: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or (C1-4)alkyl; R3 is H or (C1-4)alkyl; R4 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl; and Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or (C1-4)alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or C(O)OR wherein R is H or (C1-4)alkyl; or a salt thereof. The compounds have inhibitory activity against Wild Type, and single and double mutants strains, of HIV.

Synthesis of 7,8-disubstituted benzolactam-V8 and its binding to protein kinase C

7-methoxy-8-decynyl-benzolactam-V8 4 is synthesized using a catalytic asymmetric alkylation reaction as a key step. This compound shows potent activity to three PKC isozymes tested (Ki = 45.6, 91.1, and 121.3 nM to PKCα, δ, and ε, respectively), indicating that introduction of a suitable substituent at the 7-position of 8-decynyl-benzolactam-V8 only slightly reduces the PKC binding affinity.